•  
  •  
 

Subject Area

Dermatology

Article Type

Original Study

Abstract

Objective The aim was to compare the efficacy of intravitreal injection of aflibercept and ranibizumab in the treatment of diabetic macular edema (DME). Background Diabetic retinopathy is a microangiopathy of the retina from which nearly all persons with diabetes eventually suffer. DME is one of its complications that threaten the patient's vision. Patients and methods This is a randomized prospective study. Fifty eyes with DME were divided into two groups (each containing 25 eyes). Eyes in group I were treated with intravitreal injection of aflibercept, and eyes in group II were treated with intravitreal injection of ranibizumab. All eyes had three successive injections. The outcomes were visual acuity and central subfield macular thickness. Results The mean baseline best-corrected visual acuity (BCVA) in group I was 0.65 ± 0.12 μm and in group II was 0.63 ± 0.19 μm (P = 0.72). After 3 months, the mean BCVA in group I improved to 0.34 ± 0.16 and in group II improved to 0.44 ± 0.21 (P = 0.10). At the end of sixth month, the BCVA was 0.42 ± 0.18 in group I and0.47 ± 0.18 in group II (P = 0.23). The mean baseline central subfield thickness (CST) of eyes in group I was 523.8 ± 105.3 μm and in group II was 477.4 ± 143.6 μm (P = 0.11). After 3 months, the mean CST in eyes of group I decreased to 348.04 ± 98.4 μm, whereas in eyes of group II, the mean CST decreased to 377.5 ± 115.7 μm (P = 0.031). After 6 months, the mean CST in the eyes of the group I became 373.6 ± 139.8 μm, whereas in eyes of group II became 371.7 ± 102.3 μm (P = 0.96). Conclusion Aflibercept and ranibizumab have the same efficacy in the treatment of DME.

Download

Share

COinS